Compare Nokia Corp (NOK) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs Regeneron Pharmaceuticals Inc — how do they compare? Nokia Corp trades at $9.59 (market cap $51.87B), while Regeneron Pharmaceuticals Inc trades at $796.38 (market cap $83.19B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Nokia Corp pays the higher dividend (1.79%). Which is the better fit depends on your goals.
| NOK | REGN | |
|---|---|---|
Market Cap | $51.87B | $83.19B |
Sector | Technology | Health |
52-Week High | $16.83 | $812.27 |
52-Week Low | $4.13 | $555.51 |
Enterprise Value | $49.82B | $77.90B |
Dividend Yield | 1.79% | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $9.37, down 0.53% on the day, with a bearish technical signal and neutral oscillators. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, with Q3 results pending. Revenue for 2025 was $19.89B, with a net income margin of 3.47%. Analyst consensus is 60% buy, supported by strong cash flow from operations of $2.07B in 2025 and a focus on AI and cloud infrastructure growth.
Outlook is cautiously optimistic due to AI demand boosting earnings, but risks include telecom spending volatility and high P/E of 67.5. The stock offers growth potential from AI networking, yet investors face margin pressures and competitive threats in the telecom equipment sector.
Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.
Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
